Reneo Pharmaceuticals Analyst Ratings
Reneo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 387.8% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 10/12/2023 | 387.8% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 09/08/2023 | 387.8% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/28/2023 | 387.8% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 07/03/2023 | 273.98% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 09/19/2022 | 404.07% | HC Wainwright & Co. | → $31 | Assumes | → Buy |
| 05/18/2022 | 192.68% | Piper Sandler | $45 → $18 | Maintains | Overweight |
| 03/24/2022 | 143.9% | SVB Leerink | $25 → $15 | Maintains | Outperform |
| 01/27/2022 | 355.28% | Baird | → $28 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 355.28% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/22/2021 | 631.71% | Ladenburg Thalmann | → $45 | Initiates Coverage On | → Buy |
| 05/04/2021 | 306.5% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 05/04/2021 | 290.24% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 05/04/2021 | 631.71% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 387.8% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
| 2023 年 12 月 10 日 | 387.8% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
| 09/08/2023 | 387.8% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
| 08/28/2023 | 387.8% | HC Wainwright & Co. | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 07/03/2023 | 273.98% | B of A 类证券 | → 23 美元 | 启动覆盖范围开启 | → 购买 |
| 09/19/2022 | 404.07% | HC Wainwright & Co. | → 31 美元 | 假设 | → 购买 |
| 05/18/2022 | 192.68% | 派珀·桑德勒 | 45 美元 → 18 美元 | 维护 | 超重 |
| 2022 年 3 月 24 日 | 143.9% | SVB Leerink | 25 美元 → 15 美元 | 维护 | 跑赢大盘 |
| 01/27/2022 | 355.28% | 贝尔德 | → 28 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 12/21/2021 | 355.28% | HC Wainwright & Co. | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 11/22/2021 | 631.71% | 拉登堡塔尔曼 | → 45 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 4 月 5 日 | 306.5% | SVB Leerink | → 25 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 4 月 5 日 | 290.24% | 杰富瑞集团 | → 24 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 4 月 5 日 | 631.71% | 派珀·桑德勒 | → 45 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Reneo Pharmaceuticals (RPHM)?
瑞诺制药（RPHM）的目标价格是多少？
The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $30.00 expecting RPHM to rise to within 12 months (a possible 387.80% upside). 5 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月14日公布了瑞诺制药（纳斯达克股票代码：RPHM）的最新目标股价。该分析公司将目标股价定为30.00美元，预计RPHM将在12个月内升至12个月内（可能上涨387.80％）。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?
瑞诺制药（RPHM）的最新分析师评级是多少？
The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by HC Wainwright & Co., and Reneo Pharmaceuticals reiterated their buy rating.
HC Wainwright & Co. 提供了Reneo Pharmicals（纳斯达克股票代码：RPHM）的最新分析师评级，Reneo Pharmicals重申了其买入评级。
When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?
瑞诺制药（RPHM）的下一次分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Reneo Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Reneo Pharmicals的最新评级是在2023年11月14日公布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?
分析师对瑞诺制药（RPHM）的评级是否正确？
While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a reiterated with a price target of $0.00 to $30.00. The current price Reneo Pharmaceuticals (RPHM) is trading at is $6.15, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Reneo Pharmicals（RPHM）评级得到了重申，目标股价为0.00美元至30.00美元。Reneo Pharmicals（RPHM）目前的交易价格为6.15美元，在分析师的预测区间内。